Gary L Davis

Summary

Affiliation: Baylor University Medical Center
Country: USA

Publications

  1. ncbi request reprint A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 11:941-9. 2005
  2. ncbi request reprint New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation
    Gary L Davis
    Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, TX 75246, USA
    Liver Transpl 9:S114-9. 2003
  3. ncbi request reprint Treatment of chronic hepatitis C infection: one step at a time
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas 75246, USA
    Lancet Infect Dis 5:524-6. 2005
  4. ncbi request reprint Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
  5. ncbi request reprint New therapies: oral inhibitors and immune modulators
    Gary L Davis
    Division of Hepatology, Department of Medicine, Baylor University Medical Center, 4 Roberts, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Clin Liver Dis 10:867-80. 2006
  6. doi request reprint The healthcare burden imposed by liver disease in aging Baby Boomers
    Gary L Davis
    Departments of Medicine and Transplantation Surgery, 4 Roberts, Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Curr Gastroenterol Rep 12:1-6. 2010
  7. ncbi request reprint Thoughts on nutrition and liver disease
    Gary L Davis
    Division of Hepatology and Transplant Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Nutr Clin Pract 21:243-4. 2006
  8. ncbi request reprint Hepatitis C virus infection--pathobiology and implications for new therapeutic options
    Gary L Davis
    4 Roberts, Hepatology, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Dig Dis Sci 52:857-75. 2007
  9. ncbi request reprint Monitoring of viral levels during therapy of hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas 75246, TX, USA
    Hepatology 36:S145-51. 2002
  10. doi request reprint Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas, USA
    Gastroenterology 138:513-21, 521.e1-6. 2010

Detail Information

Publications53

  1. ncbi request reprint A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 11:941-9. 2005
    ..Further studies are required to determine whether the drug has beneficial effects in this group of patients...
  2. ncbi request reprint New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation
    Gary L Davis
    Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, TX 75246, USA
    Liver Transpl 9:S114-9. 2003
    ..5. New antiviral strategies, including use of oligonucleotides and viral enzyme inhibitors, may prove useful in the future, but these agents are just beginning to be tested in clinical trials in human beings...
  3. ncbi request reprint Treatment of chronic hepatitis C infection: one step at a time
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas 75246, USA
    Lancet Infect Dis 5:524-6. 2005
    ..Drugs that directly act on the replicative machinery of the virus-protease and polymerase inhibitors-are under development and entering clinical trials in human beings...
  4. ncbi request reprint Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  5. ncbi request reprint New therapies: oral inhibitors and immune modulators
    Gary L Davis
    Division of Hepatology, Department of Medicine, Baylor University Medical Center, 4 Roberts, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Clin Liver Dis 10:867-80. 2006
    ..It is hoped that such combinations will improve the efficacy, tolerability, and duration of antiviral treatment for this disease...
  6. doi request reprint The healthcare burden imposed by liver disease in aging Baby Boomers
    Gary L Davis
    Departments of Medicine and Transplantation Surgery, 4 Roberts, Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Curr Gastroenterol Rep 12:1-6. 2010
    ..Perhaps obesity is the greatest threat to our future health, and fatty liver disease, although likely preventable, will probably become the disease that fills the waiting rooms of future hepatologists...
  7. ncbi request reprint Thoughts on nutrition and liver disease
    Gary L Davis
    Division of Hepatology and Transplant Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Nutr Clin Pract 21:243-4. 2006
  8. ncbi request reprint Hepatitis C virus infection--pathobiology and implications for new therapeutic options
    Gary L Davis
    4 Roberts, Hepatology, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Dig Dis Sci 52:857-75. 2007
    ..This report summarizes each of the presentations sections...
  9. ncbi request reprint Monitoring of viral levels during therapy of hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas 75246, TX, USA
    Hepatology 36:S145-51. 2002
    ..Use of an early stopping rule reduces treatment costs by at least 16% and avoids the inconvenience and side effects of treatment in the 19% of patients without an EVR who have little chance of a lasting virological response...
  10. doi request reprint Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas, USA
    Gastroenterology 138:513-21, 521.e1-6. 2010
    ..The prevalence of chronic hepatitis C (CH-C) remains high and the complications of infection are common. Our goal was to project the future prevalence of CH-C and its complications...
  11. pmc Hepatocellular carcinoma: management of an increasingly common problem
    Gary L Davis
    Division of Hepatology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA
    Proc (Bayl Univ Med Cent) 21:266-80. 2008
    ..Appropriate application of these interventions offers hope of prolonged survival to many patients with this otherwise lethal complication of liver disease...
  12. ncbi request reprint Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
    Manal F Abdelmalek
    Department of Medicine, Section of Hepatobiliary Diseases University of Florida, Gainesville, FL 32610 0214, USA
    Liver Transpl 10:199-207. 2004
    ..05). In conclusion, loss of HCV after treatment of recurrent chronic hepatitis C with interferon and ribavirin is durable, and the durability of the SVR is associated with improvement in hepatic inflammation and regression of fibrosis...
  13. pmc Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
    Gut 59:1401-9. 2010
    ..The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC)...
  14. doi request reprint A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
    Goran B Klintmalm
    Baylor University Medical Center at Dallas, Dallas, TX 75246, USA
    Liver Transpl 17:1394-403. 2011
    ..5%, 75.9%, and 68.1%, respectively). Although we have found that steroid-free IS is safe and effective for liver transplant recipients with chronic HCV, steroid sparing has no clear advantage in comparison with traditional IS...
  15. ncbi request reprint The evolving treatment of chronic hepatitis C: where we stand a decade out
    Sherif Saadeh
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Cleve Clin J Med 71:S3-7. 2004
    ..This article briefly reviews how these evolving regimens for HCV infection have addressed the subtle and singular characteristics of this challenging virus...
  16. ncbi request reprint Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Gastroenterol 98:2354-62. 2003
    ..The aim of this study was to examine the economic and clinical effects of evaluating rapid viral response during antiviral therapy for treatment naive chronic hepatitis C patients...
  17. ncbi request reprint Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
    Roberto J Firpi
    Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610, USA
    Liver Transpl 8:1000-6. 2002
    ..In summary, combination therapy is a reasonable antiviral option for recurrent HCV infection for established post-LT hepatitis and appears to prevent histological progression of disease if viral eradication is successful...
  18. doi request reprint Post-liver transplant survival in hepatitis C patients is improving over time
    Jacqueline G O'Leary
    Department of Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Liver Transpl 15:360-8. 2009
    ..A major reason for this improvement is better selection of patients with concurrent hepatocellular carcinoma and fewer late cytomegalovirus infections, although other factors may play a role as well...
  19. doi request reprint Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation
    Peter T W Kim
    Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    Clin Transplant 27:311-8. 2013
    ..001) and better three-yr survival (p = 0.02) in patients meeting R4T3 criteria. Tumor biology and pre-transplant LRT are important factors that determine the post-transplant outcomes in patients with HCC who meet R4T3 criteria...
  20. ncbi request reprint Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation
    Srinath Chinnakotla
    Department of Transplant Surgery, Baylor Regional Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 15:1834-42. 2009
    ..Dyslipidemia and mouth ulcers were common but were easily controlled. In summary, the data suggest a beneficial effect of sirolimus immunosuppression on recurrence-free survival, which translates into patient survival benefits...
  21. doi request reprint Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation
    Nicholas Onaca
    Baylor Regional Transplant Institute, Dallas Fort Worth, TX 75246, USA
    Liver Transpl 15:574-80. 2009
    ..45 and 2.32, respectively). In conclusion, outcome after LTX for HCC has improved continuously over the past 20 years. Improved perioperative care and better patient selection may partially explain the improved outcome after LTX for HCC...
  22. pmc Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 7:219-26. 2009
    ..Serum fibrosis marker levels during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were determined...
  23. ncbi request reprint Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens
    Robert D Anderson
    Department of Medicine, Baylor Uinversity Medical Center and the Baylor Regional Transplant Institute, Dallas, TX, USA
    Clin Transplant 21:510-7. 2007
    ..Graft loss is usually avoidable when recurrence is discovered early and aggressively treated. The IM route is preferable to IV administration due to its ease of administration and lower cost...
  24. ncbi request reprint Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect
    David R Nelson
    Department of Medicine, University of Florida, 1600 S W Archer Road, PO Box 100214, Gainesville, FL 32610 0214, USA
    Hepatology 38:859-68. 2003
    ..In conclusion, long-term rIL-10 therapy appears to decrease disease activity, but also leads to increased HCV viral burden via alterations in immunologic viral surveillance...
  25. doi request reprint Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants
    Jacqueline G O'Leary
    Annette C and Harold C Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas, USA
    Clin Gastroenterol Hepatol 9:700-704.e1. 2011
    ..Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT)...
  26. doi request reprint Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined
    Jacqueline G O'Leary
    Annette C and Harold C Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    Transpl Int 25:825-9. 2012
    ..In conclusion, approximately half of HCV antibody-positive donors were aviremic. Viral dominance in viremic donor-recipient pairs seems virally determined...
  27. pmc Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C
    Anna S Lok
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 54:434-42. 2011
    ..7% of controls. HBV DNA was detected in the serum of only one control subject and no patients with HCC. HBV DNA (as a marker of occult HBV infection) was detected in the livers of 10.7% of HCC cases and 23.6% of controls (P=0.18)...
  28. ncbi request reprint Chronic hepatitis C and liver transplantation
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, Texas, USA
    Rev Gastroenterol Disord 4:7-17. 2004
    ..Furthermore, the system raises difficult ethical issues of utilization of limited resources and fairness to other transplant candidates...
  29. doi request reprint Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology
    Srinath Chinnakotla
    Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    Transplantation 92:341-5. 2011
    ....
  30. ncbi request reprint Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation
    Nicholas Onaca
    Baylor Regional Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 13:391-9. 2007
    ..1-5.0 cm or 2-3 lesions all < or =3 cm in diameter. These data suggest that current criteria for selecting tumor patients for LT may be too restrictive and could be expanded...
  31. ncbi request reprint Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease
    Kanthi Yalamanchili
    Departments of Medicine, Baylor University Medical Center, Dallas, TX, USA
    Liver Transpl 16:431-9. 2010
    ..Posttransplant NASH is unusual, and steatosis appears to be a prerequisite. Advanced fibrosis is uncommon, and survival is the same as that of patients who undergo transplantation for other causes...
  32. pmc Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C
    Richard W Lambrecht
    Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
    Gastroenterology 140:1490-500.e3. 2011
    ..Our aim was to assess the relationship of iron and HFE genetic variations to progression and outcomes in the HALT-C Trial and whether PegIFN therapy influenced iron variables...
  33. doi request reprint Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation
    John K O'Connor
    Baylor Radiosurgery Center, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 18:949-54. 2012
    ..SBRT for HCC may enable patients to remain on the list for frequently curative transplantation during the wait for organ availability...
  34. ncbi request reprint Projecting future complications of chronic hepatitis C in the United States
    Gary L Davis
    Division of Hepatology, Baylor Regional Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 9:331-8. 2003
    ..These data emphasize the need for greater access to transplantation by expansion of the donor pool, increasing use of split livers and living donors, and novel options such as xenotransplantation...
  35. ncbi request reprint Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection
    Roberto J Firpi
    Section of Hepatobiliary Diseases, Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, PO Box 100214, JHMHC, Gainesville, FL 32610 0214, USA
    Liver Transpl 9:57-61. 2003
    ..The most common side effects were headache, nausea, and diarrhea. Mycophenolate alone does not appear to have a significant antiviral or biochemical effect in patients with chronic hepatitis C...
  36. doi request reprint Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease
    Jacqueline G O'Leary
    Division of Hepatology, Department of Medicine, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 15:1325-9. 2009
    ..Further study in a prospective clinical trial is needed to confirm safety and efficacy...
  37. doi request reprint Indications for liver transplantation
    Jacqueline G O'Leary
    Hepatology, Department of Medicine, Baylor University Medical Center, Dallas, Texas 75246, USA
    Gastroenterology 134:1764-76. 2008
    ..Since 2002, priority for transplantation has been determined by the Model of End-Stage Liver Disease (MELD) score, which provides donor organs to listed patients with the highest estimated short-term mortality...
  38. ncbi request reprint An outcome comparison between primary liver transplantation and retransplantation based on the pretransplant MELD score
    Nicholas Onaca
    Transplant Services, Baylor University Medical Center, Dallas, TX 75204, USA
    Transpl Int 19:282-7. 2006
    ..82). Late RLTX is marked by poor survival regardless of the pretransplant MELD score. The MELD-based allocation system may not benefit patients who undergo retransplantation...
  39. ncbi request reprint Management of ascites in patients with end-stage liver disease
    Sherif Saadeh
    Division of Hepatology, Baylor University Medical Center, Dallas, Texas, USA
    Rev Gastroenterol Disord 4:175-85. 2004
    ..Orthotopic liver transplantation should be considered in all patients with decompensated liver disease with or without ascites...
  40. ncbi request reprint Update on the management of chronic hepatitis B
    Gary L Davis
    Section of Hepatobiliary Disease, Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA
    Rev Gastroenterol Disord 2:106-15. 2002
    ..Newer agents, such as lamivudine and adefovir dipivoxil, offer excellent antiviral activity and ease of administration, although drug resistance is common with lamivudine...
  41. ncbi request reprint Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer
    Xianglin L Du
    Division of Epidemiology, School of Public Health, The University of Texas Health Science Center, Houston, Texas, USA
    Cancer 110:660-9. 2007
    ..To the authors' knowledge, few studies have addressed racial disparities in the survival of patients with colon cancer by adequately incorporating treatment and socioeconomic factors in addition to patient and tumor characteristics...
  42. ncbi request reprint Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus
    Thomas P Giordano
    Department of Medicine, Baylor College of Medicine, and The Houston Center for Quality of Care and Utilization Studies, Michael E DeBakey Veterans Affairs Medical Center, Houston, Tex 77030, USA
    JAMA 297:2010-7. 2007
    ..Previous studies have been too small to adequately assess these risks...
  43. ncbi request reprint Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
    ..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
  44. ncbi request reprint Best of the AASLD. Highlights from the 52nd Annual Meeting of the American Association for the Study of Liver Diseases. November 9-13, 2001, Dallas, TX
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA
    Rev Gastroenterol Disord 2:34-40. 2002
  45. ncbi request reprint Tailoring antiviral therapy in hepatitis C
    Gary L Davis
    Hepatology 43:909-11. 2006
  46. ncbi request reprint Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills?
    Gary L Davis
    Liver Transpl 12:1317-9. 2006
  47. ncbi request reprint The challenge of progressive hepatitis C following liver transplantation
    Gary L Davis
    Liver Transpl 12:19-21. 2006
  48. ncbi request reprint A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:35-45. 2006
    ..These results support further clinical studies of albumin-IFN-alpha for the treatment of patients with chronic hepatitis C...
  49. ncbi request reprint Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse
    Mustafa al'Absi
    Department of Behavioral Sciences, University of Minnesota Medical School, 1035 University Drive, Duluth, MN 55812 2487, USA
    Psychopharmacology (Berl) 181:107-17. 2005
    ..Research has demonstrated that psychosocial stressors increase smoking and risk for smoking relapse. Alterations in biological systems involved in the stress response caused by chronic smoking may contribute to early relapse...
  50. ncbi request reprint Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse
    Mustafa al'Absi
    Department of Behavioral Sciences, University of Minnesota Medical School, Duluth, MN 55812 2487, USA
    Drug Alcohol Depend 73:267-78. 2004
    ..These results support the hypothesis that early relapse is associated with exaggerated mood and adrenocortical perturbations observed during the first day of abstinence...
  51. ncbi request reprint A microplate assay specific for the enzyme aggrecanase
    Jeffery A Miller
    The Bristol Myers Squibb Company Pharmaceutical Research Institute, Experimental Station, Route 141 and Henry Clay Road, Wilmington, DE 19880, USA
    Anal Biochem 314:260-5. 2003
    ....
  52. doi request reprint Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis
    Mansour A Parsi
    Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Gastroenterology 135:803-7. 2008
    ..The aim of this study was to assess the utility of ascitic fluid lactoferrin (AFLAC) for the diagnosis of SBP and to identify a cut-off level that can be used for future development of a rapid bedside test...
  53. doi request reprint Future trends in hepatology: challenges and opportunities
    Vinod K Rustgi
    Transplant Surgery, Georgetown University, Fairfax, VA, USA
    Hepatology 48:655-61. 2008